HCM - HUTCHMED (China) Ltd

QQQ $ 611.05 $ 0.00 (0 %)

DIA $ 466.97 $ 0.00 (0 %)

SPY $ 671.70 $ 0.00 (0 %)

TLT $ 91.40 $ 0.00 (0 %)

GLD $ 378.30 $ 0.00 (0 %)

Previous Close

$ 15.11

Open

$ 15.03

Bid

$ 14.85 x 25

Ask

$ 15.68 x 200

Day's Range

$ 14.92 - $ 15.11

52 Week Range

$ 11.51 - $ 21.50

Volume

14,242

Average Volume

Market Cap

2.63B

Beta (5Y Monthly)

$ 1.07

PE Ratio (TTM)

$ 69.81

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HUTCHMED Presents HMPL-A251 Preclinical Da...
10/23/2025 06:59:44

First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads whi...

HUTCHMED Highlights FRUSICA-2 Data At ESMO...
10/13/2025 06:17:44

Reported Earlier, HUTCHMED To Present New ...
10/02/2025 06:24:10

new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Med...

Morgan Stanley Downgrades HUTCHMED (China)...
09/22/2025 17:20:15

Morgan Stanley analyst Jack Lin downgrades HUTCHMED (China) (NASDAQ:HCM) from Equal-Weight to Underweight and lowers the pri...

ibex-tesla-ionq-warner-bros-discovery-and-other-big-stocks-moving-higher-on-friday

IBEX, Tesla, IonQ, Warner Bros. Discovery ...
09/12/2025 14:24:09

Reported Earlier, HUTCHMED To Present Upda...
09/05/2025 06:55:30

Reported Sunday, HUTCHMED Appoints Johnny ...
08/25/2025 06:29:22

Reported Earlier, HUTCHMED Progresses SANO...
08/20/2025 07:23:34

CORRECTION: HUTCHMED (China) H1 EPADS $2.6...
08/07/2025 11:43:05

Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

B of A Securities Maintains Buy on HUTCHME...
07/22/2025 16:14:52

B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and raises the price target from $...

HUTCHMED Receives China NMPA Approval For ...
06/30/2025 08:53:21

Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum...

Reported Earlier, HUTCHMED And Innovent Se...
06/05/2025 07:37:45

Reported Sunday, HUTCHMED Highlights SACHI...
06/02/2025 06:22:06

— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favora...

Reported Earlier, HUTCHMED To Present New ...
05/23/2025 06:59:05

Reported Earlier, HUTCHMED To Present New ...
04/24/2025 07:25:41

Reported Earlier, HUTCHMED Wraps Enrollmen...
04/22/2025 05:33:40

The China's National Medical Products Administration ("NMPA") has granted Breakthrough Therapy Designation to savol...

progress-software-posts-upbeat-results-joins-microvast-pvh-and-other-big-stocks-moving-higher-on-tuesday

Progress Software Posts Upbeat Results, Jo...
04/01/2025 14:32:43

$hutchmed-announces-that-the-new-drug-application-for-tazverik-tazemetostat-has-been-granted-conditional-approval-in-china-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-follicular-lymphoma-with-ezh2-mutation-who-have-received-at-least-two-prior-systemic-therapies$

HUTCHMED Announces That The New Drug Appli...
03/21/2025 10:03:27

Reported Earlier, HUTCHMED Presents SAVANN...
03/20/2025 07:22:00

SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, r...